Stock Research: Chugai Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Chugai Pharmaceutical

TSE:4519 JP3519400000
63
  • Value
    86
  • Growth
    62
  • Safety
    Safety
    20
  • Combined
    61
  • Sentiment
    61
  • 360° View
    360° View
    63
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Chugai Pharmaceutical Co Ltd is a Japan-based company that researches, develops, manufactures, and sells pharmaceutical products. The company operates in the pharmaceutical industry, with products for treating cancer, kidney diseases, and other conditions. It operates in Japan, Switzerland, the United Kingdom, Germany, France, China, Singapore, Korea, and the United States. In the last fiscal year, the company had a market cap of $76,700 million, profits of $5,298 million, and revenue of $7,448 million with 7778 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 63 (better than 63% compared with alternatives), overall professional sentiment and financial characteristics for the stock Chugai Pharmaceutical are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Chugai Pharmaceutical. The consolidated Growth Rank has a good rank of 62, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 62% of competitors in the same industry. The consolidated Safety Rank at 86 means that the company has a financing structure that is safer than 86% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 61, which means that professional investors are more optimistic about the stock than for 61% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 20, meaning that the share price of Chugai Pharmaceutical is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 80% of alternative stocks in the same industry. ...read more

more
Index
TOPIX 100
Renewables Users
Nikkei 225
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
20 20 20 35
Growth
62 47 37 23
Safety
Safety
86 80 84 78
Sentiment
61 82 70 58
360° View
360° View
63 42 51 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
45 35 63 37
Opinions Change
50 77 60 50
Pro Holdings
n/a 98 60 96
Market Pulse
42 50 56 24
Sentiment
61 82 70 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
20 20 20 35
Growth
62 47 37 23
Safety Safety
86 80 84 78
Combined
61 47 39 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
45 28 33 60
Price vs. Earnings (P/E)
10 9 11 24
Price vs. Book (P/B)
14 15 14 18
Dividend Yield
59 49 49 70
Value
20 20 20 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
43 29 13 33
Profit Growth
67 37 26 69
Capital Growth
36 47 42 48
Stock Returns
68 82 95 15
Growth
62 47 37 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
91 60 87 80
Refinancing
38 21 33 29
Liquidity
100 100 100 98
Safety Safety
86 80 84 78

Similar Stocks

Discover high‑ranked alternatives to Chugai Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Daiwabo Holdings

TSE:3107
Country: Japan
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Isuzu Motors

TSE:7202
Country: Japan
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.